{"filing":{"accession_number":"0001104659-26-065728","cik":"0001829635","ticker":"RNAZ","company_name":"Transcode Therapeutics, Inc.","form":"8-K","filing_date":"2026-05-22","report_date":null,"primary_document":"tm2615385d1_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1829635/000110465926065728/tm2615385d1_8k.htm"},"events":[{"id":10491,"run_id":9200,"accession_number":"0001104659-26-065728","anchor_item_number":"3.01","event_type":"delisting_risk","event_domain":"terminal","is_material":true,"confidence":0.98,"summary":"TransCode Therapeutics received a deficiency letter from Nasdaq on May 19, 2026, notifying the company that it failed to maintain the minimum stockholders' equity requirement of $2,500,000 for continued listing on the Nasdaq Capital Market, with reported stockholders' equity of only $1,251,427 as of March 31, 2026. The company has 45 days to submit a compliance plan, and failure to regain compliance could result in delisting. This is a classic delisting risk disclosure under Item 3.01.","company_name":"Transcode Therapeutics, Inc.","ticker":"RNAZ","filing_date":"2026-05-22","submitted_at":null,"items":[{"id":6818,"accession_number":"0001104659-26-065728","item_number":"3.01","item_title":null,"event_type":"delisting_risk","event_domain":"terminal","is_material":true,"confidence":0.98,"reasoning":"TransCode Therapeutics received a deficiency letter from Nasdaq on May 19, 2026, notifying the company that it failed to maintain the minimum stockholders' equity requirement of $2,500,000 for continued listing on the Nasdaq Capital Market, with reported stockholders' equity of only $1,251,427 as of March 31, 2026. The company has 45 days to submit a compliance plan, and failure to regain compliance could result in delisting. This is a classic delisting risk disclosure under Item 3.01.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-13T00:24:13.264436+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":6818,"accession_number":"0001104659-26-065728","item_number":"3.01","item_title":null,"event_type":"delisting_risk","event_domain":"terminal","is_material":true,"confidence":0.98,"reasoning":"TransCode Therapeutics received a deficiency letter from Nasdaq on May 19, 2026, notifying the company that it failed to maintain the minimum stockholders' equity requirement of $2,500,000 for continued listing on the Nasdaq Capital Market, with reported stockholders' equity of only $1,251,427 as of March 31, 2026. The company has 45 days to submit a compliance plan, and failure to regain compliance could result in delisting. This is a classic delisting risk disclosure under Item 3.01.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-13T00:24:13.264436+00:00","company_name":"Transcode Therapeutics, Inc.","ticker":"RNAZ","filing_date":"2026-05-22"}]}